Trial Profile
A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs DM 199 (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms REDUX
- Sponsors DiaMedica Therapeutics
- 16 Mar 2022 Status changed from active, no longer recruiting to completed.
- 14 Mar 2022 According to a DiaMedica Therapeutics media release, interim data were presented at the American Society of Nephrology annual Kidney Week meeting in November 2021.
- 14 Mar 2022 According to a DiaMedica Therapeutics media release, last patient has been dosed.